Optimal therapy of hepatitis C

Hepatology

Volumn 36, Issue 5, 2002, Pages S121-S127

  Di Bisceglie, Adrian M ^a   Hoofnagle, Jay H ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 0036829751     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.36228     Document Type: Article

References (10)

1. National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology 1997;26:2S-10S.
2. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999;19:57-65.
3. Glue P, Fang JWS, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, et al. Pegylated interferon-a2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000;68:556-567.
4. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncitrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-438.
5. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai M-Y, Gane E, O'Grady J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
6. Heathcote EJ, Shiffman ML, Cooksley WGE, Dusheiko GM, Lee SS, Balart L, Reindollar R, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680.
7. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, et al. A randomized, double blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with intetfeton alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-965
9. Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Goncales FL Jr, Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C vitus infection. N Engl J Med 2002;347:975-982.
10. Hadziyannis SJ, Cheinquer H, Morgan T, Diago M, Jensen DM, Sette H, Ramadori G, et al. Peginterfeton alfa-2a (40kD) (PEGASYS) in combination with ribavirin (RBV): Efficacy and safety results from a phase III, tandomized, double-blind multicentte study examining effect of duration of treatment and RBV dose. J Hepatol 2002;36(suppl 1):3.